HHS disseminates $6B for children's insurance

Health & Human Services Secretary (HHS) Kathleen Sebelius has reported that $6 billion in new federal funds will be made available to states and U.S. territories for fiscal year 2009 to provide health care to millions of children across the United States through their Children's Health Insurance Programs (CHIP).

The new funds for CHIP were made available by the Children's Health Insurance Program Reauthorization Act of 2009 (CHIPRA), which was signed into law by President Barack Obama on February 4. CHIPRA provides additional funding that will help states and territories maintain existing CHIP enrollment and expand their programs.

In addition to increased funding, CHIPRA revised the annual allotment formula to better reflect projected state and program spending.

"Through CHIPRA, states and territories will receive additional funds to provide health insurance to 11 million children, including 4 million who were previously uninsured. Parents now have more help if their children fall ill," Sebelius said.

Of the $6 billion in new funding under CHIPRA, HHS said it has released more than $1 billion and expects to allocate the remainder to the states and territories by the end of September.

CHIP provides health insurance for children of working families whose incomes are too high for traditional Medicaid, but too low for either employer-sponsored family plans or other private coverage, according to the agency. While CHIP is optional, each state and every territory operates a program. Similar to Medicaid, CHIP is jointly funded by states and the federal government.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.